Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2021

18.10.2021 | review

Practical considerations for the management of immune thrombocytopenic purpura

verfasst von: Michael Fillitz, Barbara Dixer, Felix Keil

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Immune thrombocytopenic purpura (ITP) is a rare hematological disorder with an autoimmune-mediated, often dramatic reduction of platelets in peripheral blood. Thrombocytopenia results from a reduced life span of thrombocytes and an additionally decreased production in bone marrow. For decades, the first-line therapy for ITP has been corticosteroids. As significant thrombocytopenic bleedings occur, the use of additional medication may be needed. Recent updates on therapy guidelines recommend the shortest possible use of corticosteroids. Thrombopoietin-receptor agonists are often used second line. Today splenectomy, which was previously recommended after unsuccessful first-line therapy, is usually considered much later. Patients who do not respond even after multiple lines of therapy continue to pose a major challenge. New drugs for ITP treatment are now available after steroid failure and will be discussed. This review gives a short summary on actual therapy guidelines taking into account newly available therapy options. In addition, comparisons between selected published data and experience at our department are made.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Lim JH, et al. Epidemiology and viral etiology of pediatric immune thrombocytopenia through Korean Public Health Data Analysis. J Clin Med. 2021;10:1356. CrossRef Lim JH, et al. Epidemiology and viral etiology of pediatric immune thrombocytopenia through Korean Public Health Data Analysis. J Clin Med. 2021;10:1356. CrossRef
2.
Zurück zum Zitat Barcellini W, et al. Autoimmune complications in hematologic neoplasms. Cancers. 2021;13(7):1532. CrossRef Barcellini W, et al. Autoimmune complications in hematologic neoplasms. Cancers. 2021;13(7):1532. CrossRef
3.
Zurück zum Zitat Zhang F, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427–31. CrossRef Zhang F, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427–31. CrossRef
7.
Zurück zum Zitat Li L, Zhao Y, Tong X, Li Y, Huang L, Hui Y, Mao X, Wei J, Shang Z, Wang L, Xiang H, Guo J, Chang W, Zhang X, Liu L, Gao K, Zhang D. The predictive value of regulatory T cells on glucocorticoid sensitivity in patients with immune thrombocytopenia: a multicentre, prospective clinical study. Br J Haematol. 2021;193(3):619–627. https://​doi.​org/​10.​1111/​bjh.​17368. CrossRefPubMed Li L, Zhao Y, Tong X, Li Y, Huang L, Hui Y, Mao X, Wei J, Shang Z, Wang L, Xiang H, Guo J, Chang W, Zhang X, Liu L, Gao K, Zhang D. The predictive value of regulatory T cells on glucocorticoid sensitivity in patients with immune thrombocytopenia: a multicentre, prospective clinical study. Br J Haematol. 2021;193(3):619–627. https://​doi.​org/​10.​1111/​bjh.​17368. CrossRefPubMed
8.
Zurück zum Zitat Arai Y, et al. Efficacy of dexamethasone for acute primary immune thrombocytopenia compared to prednisolone: a systematic review and meta-analysis. Th Open. 2017;1:e73–e81. CrossRef Arai Y, et al. Efficacy of dexamethasone for acute primary immune thrombocytopenia compared to prednisolone: a systematic review and meta-analysis. Th Open. 2017;1:e73–e81. CrossRef
9.
Zurück zum Zitat Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66. CrossRef Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66. CrossRef
10.
Zurück zum Zitat Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–817. CrossRef Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–817. CrossRef
11.
Zurück zum Zitat Vianelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia. A retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98(6):875–80. CrossRef Vianelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia. A retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98(6):875–80. CrossRef
12.
Zurück zum Zitat Chugh S, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–e81. CrossRef Chugh S, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–e81. CrossRef
13.
Zurück zum Zitat Patel VL, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95. CrossRef Patel VL, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95. CrossRef
14.
Zurück zum Zitat Michel M, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020;136(26):3056–61. CrossRef Michel M, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020;136(26):3056–61. CrossRef
15.
Zurück zum Zitat Neunert CE, et al. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv. 2019;25; 3(12):1907–15. Jun. CrossRef Neunert CE, et al. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv. 2019;25; 3(12):1907–15. Jun. CrossRef
16.
Zurück zum Zitat Forsythe A, et al. Real world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020;9(7):447–57. PubMed Forsythe A, et al. Real world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020;9(7):447–57. PubMed
17.
Zurück zum Zitat Gonzalez-Lopez TJ, et al. Sucessful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–E3. CrossRef Gonzalez-Lopez TJ, et al. Sucessful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–E3. CrossRef
18.
Zurück zum Zitat Boccia R et al. Enhanced responses to Fostamatinib as second-line therapy and in persistent Immune Thrombocytopenia (ITP) patients. Blood (2019), Volume 134, Issue Supplement 1,1069. Boccia R et al. Enhanced responses to Fostamatinib as second-line therapy and in persistent Immune Thrombocytopenia (ITP) patients. Blood (2019), Volume 134, Issue Supplement 1,1069.
19.
Zurück zum Zitat Howard J, et al. Mycophenolate mofetil for the treatment of refractory auto immune haemolytic anemia and auto immune thrombocytopenia purpura. Br J Haematol. 2002;117:712–5. CrossRef Howard J, et al. Mycophenolate mofetil for the treatment of refractory auto immune haemolytic anemia and auto immune thrombocytopenia purpura. Br J Haematol. 2002;117:712–5. CrossRef
20.
Zurück zum Zitat Zhang W, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Chung Kuo Yao Li Hsueh Pao. 2005;26(5):598–602. PubMed Zhang W, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Chung Kuo Yao Li Hsueh Pao. 2005;26(5):598–602. PubMed
21.
Zurück zum Zitat Pell J et al. Trial protocol. a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The Flight Trial. Bmj Open. 2018;8:e24427. CrossRef Pell J et al. Trial protocol. a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The Flight Trial. Bmj Open. 2018;8:e24427. CrossRef
22.
Zurück zum Zitat Du Y, et al. Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study. Hematology. 2020;25(1):478–83. CrossRef Du Y, et al. Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study. Hematology. 2020;25(1):478–83. CrossRef
Metadaten
Titel
Practical considerations for the management of immune thrombocytopenic purpura
verfasst von
Michael Fillitz
Barbara Dixer
Felix Keil
Publikationsdatum
18.10.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00771-9